Exagen director Ana Hooker resigns from board
Exagen Inc. reported that director Ana Hooker resigned from its Board of Directors, including all committee positions, effective April 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Exagen Inc. reported that director Ana Hooker resigned from its Board of Directors, including all committee positions, effective April 17, 2026. She had served on the Audit Committee and as chair of the Nominating and Corporate Governance Committee. The company stated her resignation was not due to any disagreement regarding operations, policies, or practices.
Following her departure, the Board size was reduced from eight to seven members, and committee memberships were realigned among remaining directors.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Board size after resignation: 7 directors
Board size before resignation: 8 directors
Effective date of resignation: April 17, 2026
3 metrics
Board size after resignation
7 directors
Effective April 17, 2026 following Ana Hooker’s departure
Board size before resignation
8 directors
Prior to April 17, 2026
Effective date of resignation
April 17, 2026
Ana Hooker’s resignation and board reconstitution
Key Terms
Audit Committee, Nominating and Corporate Governance Committee, Emerging growth company, Financial Expert
4 terms
Audit Committee financial
"Ms. Hooker was a member of the Audit Committee and chair of the Nominating"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Nominating and Corporate Governance Committee financial
"chair of the Nominating and Corporate Governance Committee."
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Financial Expert financial
"C Committee Chairman † Financial Expert"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Exagen (XGN) announce in this 8-K filing?
Exagen announced that board member Ana Hooker resigned from the Board and all its committees effective April 17, 2026. The company also reduced the Board size from eight to seven directors and updated committee assignments among the remaining members.
Why did Ana Hooker resign from Exagen (XGN)’s Board of Directors?
Exagen disclosed that Ana Hooker chose to resign from the Board effective April 17, 2026. The company specifically stated that her decision was not due to any disagreement regarding Exagen’s operations, policies, or practices, indicating no reported governance dispute.
How did Ana Hooker’s resignation affect Exagen (XGN)’s Board structure?
After Ana Hooker’s resignation, Exagen reduced the size of its Board from eight to seven members. The company also reconstituted its Audit, Compensation, and Nominating and Corporate Governance Committees, assigning existing directors to fill the necessary roles and chair positions.
What board committees did Ana Hooker serve on at Exagen (XGN)?
Before resigning, Ana Hooker served as a member of Exagen’s Audit Committee and as chair of the Nominating and Corporate Governance Committee. Her departure required the Board to adjust committee memberships and leadership among the remaining directors effective April 17, 2026.
Who now chairs key Exagen (XGN) board committees after the change?
Following the restructuring, Frank Stokes serves as chair of the Audit Committee, and Scott D. Kahn, Ph.D., chairs the Nominating and Corporate Governance Committee. Committee memberships for other directors were also updated as of the April 17, 2026 effective time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates